会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • THERAPEUTIC PEPTIDES
    • 治疗肽
    • WO1990003980A1
    • 1990-04-19
    • PCT/US1989004616
    • 1989-10-13
    • ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    • ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDCOY, David, H.MOREAU, Jacques-PierreTAYLOR, John, E.KIM, Sun, Hyuk
    • C07K07/02
    • C07K14/57572A61K38/00C07K7/02C07K7/086
    • In general, the invention features a linear (i.e., non-cyclic) bombesin analog of biologically active mammalian gastrin-releasing peptide (GRP) and amphibian bombesin, having an active site and a binding site responsable for the binding of the peptide to a receptor on a target cell; cleavage of a peptide bond in the active site of naturally occuring bombesin or GRP is unnecessary for in vivo bilogical activity. The analog has one of the following modifications: (a) a deletion of a residue within the active site and a modification of a residue outside of the active site, or (b) a remplacement of one or two residues within the active site with a synthetic amino acid. The analog is capable of binding to the receptor and acting as a competitive inhibitor of the naturally occurring peptide by binding to the receptor and, by virtue of one of the modifications, failing to exhibit the in vivo biological activity of the naturally occurring peptide.
    • 通常,本发明的特征在于具有生物活性的哺乳动物胃泌素释放肽(GRP)和两栖动物铃蟾肽的线性(即非环状)铃蟾肽类似物,具有活性位点和对肽结合受体负责的结合位点 在目标细胞上 天然存在的铃蟾肽或GRP的活性位点中肽键的切割对于体内生物活性是不必要的。 类似物具有以下修改之一:(a)活性位点内的残基的缺失和活性位点之外的残基的修饰,或(b)活性位点内的一个或两个残基的置换, 合成氨基酸。 类似物能够结合受体并且通过与受体结合而作为天然存在的肽的竞争性抑制剂,并且通过其中一个修饰,不能显示天然存在的肽的体内生物活性。